2025年7月,神经AI技术领域的领军企业Fasikl公司宣布,其自主研发的Felix™ NeuroAI™腕带已获得美国食品药品监督管理局(FDA)批准,用于治疗成人原发性震颤引起的上肢功能障碍。Felix 腕带是全球首款且唯一获得FDA批准、基于人工智能(AI)的原发性震颤治疗设备,开创了AI治疗新时代。该设备通过云端AI技术,实现实时、个性化的神经调控治疗,既可单独使用,也可联合药物治疗,为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.